Literature DB >> 30891627

The pathogenicity of Th17 cells in autoimmune diseases.

Keiko Yasuda1,2, Yusuke Takeuchi1,3, Keiji Hirota4.   

Abstract

IL-17-producing T helper (Th17) cells have been implicated in the pathogenesis of many inflammatory and autoimmune diseases. Targeting the effector cytokines IL-17 and GM-CSF secreted by autoimmune Th17 cells has been shown to be effective for the treatment of the diseases. Understanding a molecular basis of Th17 differentiation and effector functions is therefore critical for the regulation of the pathogenicity of tissue Th17 cells in chronic inflammation. Here, we discuss the roles of proinflammatory cytokines and environmental stimuli in the control of Th17 differentiation and chronic tissue inflammation by pathogenic Th17 cells in humans and in mouse models of autoimmune diseases. We also highlight recent advances in the regulation of pathogenic Th17 cells by gut microbiota and immunometabolism in autoimmune arthritis.

Entities:  

Keywords:  Autoimmune arthritis; EAE; GM-CSF; IL-17; Rheumatoid arthritis; Th17 cells

Year:  2019        PMID: 30891627     DOI: 10.1007/s00281-019-00733-8

Source DB:  PubMed          Journal:  Semin Immunopathol        ISSN: 1863-2297            Impact factor:   9.623


  145 in total

1.  Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells.

Authors:  Estelle Bettelli; Yijun Carrier; Wenda Gao; Thomas Korn; Terry B Strom; Mohamed Oukka; Howard L Weiner; Vijay K Kuchroo
Journal:  Nature       Date:  2006-04-30       Impact factor: 49.962

2.  Interleukin-23-Induced Transcription Factor Blimp-1 Promotes Pathogenicity of T Helper 17 Cells.

Authors:  Renu Jain; Yi Chen; Yuka Kanno; Barbara Joyce-Shaikh; Golnaz Vahedi; Kiyoshi Hirahara; Wendy M Blumenschein; Selvakumar Sukumar; Christopher J Haines; Svetlana Sadekova; Terrill K McClanahan; Mandy J McGeachy; John J O'Shea; Daniel J Cua
Journal:  Immunity       Date:  2015-12-29       Impact factor: 31.745

3.  A randomised phase IIb study of mavrilimumab, a novel GM-CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis.

Authors:  Gerd R Burmester; Iain B McInnes; Joel Kremer; Pedro Miranda; Mariusz Korkosz; Jiri Vencovsky; Andrea Rubbert-Roth; Eduardo Mysler; Matthew A Sleeman; Alex Godwood; Dominic Sinibaldi; Xiang Guo; Wendy I White; Bing Wang; Chi-Yuan Wu; Patricia C Ryan; David Close; Michael E Weinblatt
Journal:  Ann Rheum Dis       Date:  2017-02-17       Impact factor: 19.103

4.  Control of T(H)17/T(reg) balance by hypoxia-inducible factor 1.

Authors:  Eric V Dang; Joseph Barbi; Huang-Yu Yang; Dilini Jinasena; Hong Yu; Ying Zheng; Zachary Bordman; Juan Fu; Young Kim; Hung-Rong Yen; Weibo Luo; Karen Zeller; Larissa Shimoda; Suzanne L Topalian; Gregg L Semenza; Chi V Dang; Drew M Pardoll; Fan Pan
Journal:  Cell       Date:  2011-08-25       Impact factor: 41.582

5.  Complement drives Th17 cell differentiation and triggers autoimmune arthritis.

Authors:  Motomu Hashimoto; Keiji Hirota; Hiroyuki Yoshitomi; Shinji Maeda; Shin Teradaira; Shuji Akizuki; Paz Prieto-Martin; Takashi Nomura; Noriko Sakaguchi; Jörg Köhl; Birgitta Heyman; Minoru Takahashi; Teizo Fujita; Tsuneyo Mimori; Shimon Sakaguchi
Journal:  J Exp Med       Date:  2010-05-10       Impact factor: 14.307

6.  Gamma/delta T cells are the predominant source of interleukin-17 in affected joints in collagen-induced arthritis, but not in rheumatoid arthritis.

Authors:  Yoshinaga Ito; Takashi Usui; Shio Kobayashi; Mikiko Iguchi-Hashimoto; Hiromu Ito; Hiroyuki Yoshitomi; Takashi Nakamura; Masakazu Shimizu; Daisuke Kawabata; Naoichiro Yukawa; Motomu Hashimoto; Noriko Sakaguchi; Shimon Sakaguchi; Hajime Yoshifuji; Takaki Nojima; Koichiro Ohmura; Takao Fujii; Tsuneyo Mimori
Journal:  Arthritis Rheum       Date:  2009-08

7.  The MicroRNA-183-96-182 Cluster Promotes T Helper 17 Cell Pathogenicity by Negatively Regulating Transcription Factor Foxo1 Expression.

Authors:  Kenji Ichiyama; Alicia Gonzalez-Martin; Byung-Seok Kim; Hyun Yong Jin; Wei Jin; Wei Xu; Mohsen Sabouri-Ghomi; Shunbin Xu; Pan Zheng; Changchun Xiao; Chen Dong
Journal:  Immunity       Date:  2016-06-21       Impact factor: 31.745

8.  A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis.

Authors:  Kenneth B Gordon; Craig L Leonardi; Mark Lebwohl; Andrew Blauvelt; Gregory S Cameron; Daniel Braun; Janelle Erickson; Michael Heffernan
Journal:  J Am Acad Dermatol       Date:  2014-09-19       Impact factor: 11.527

9.  TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells.

Authors:  Marc Veldhoen; Richard J Hocking; Christopher J Atkins; Richard M Locksley; Brigitta Stockinger
Journal:  Immunity       Date:  2006-02       Impact factor: 31.745

10.  Induction and molecular signature of pathogenic TH17 cells.

Authors:  Youjin Lee; Amit Awasthi; Nir Yosef; Francisco J Quintana; Sheng Xiao; Anneli Peters; Chuan Wu; Markus Kleinewietfeld; Sharon Kunder; David A Hafler; Raymond A Sobel; Aviv Regev; Vijay K Kuchroo
Journal:  Nat Immunol       Date:  2012-09-09       Impact factor: 25.606

View more
  89 in total

1.  Pathogenicity of acquired immunity in human diseases.

Authors:  Kiyoshi Hirahara
Journal:  Semin Immunopathol       Date:  2019-05-07       Impact factor: 9.623

2.  Extracellular vesicles of bacteria as potential targets for immune interventions.

Authors:  Yizhi Peng; Sheng Yin; Min Wang
Journal:  Hum Vaccin Immunother       Date:  2020-09-01       Impact factor: 3.452

Review 3.  Mode of Action of Aspirin in Experimental Autoimmune Encephalomyelitis.

Authors:  Swarupa Pahan; Kalipada Pahan
Journal:  DNA Cell Biol       Date:  2019-05-28       Impact factor: 3.311

Review 4.  Potential application of helminth therapy for resolution of neuroinflammation in neuropsychiatric disorders.

Authors:  Amir Abdoli; Hoda Mirzaian Ardakani
Journal:  Metab Brain Dis       Date:  2019-07-27       Impact factor: 3.584

5.  JQ1, a bromodomain inhibitor, suppresses Th17 effectors by blocking p300-mediated acetylation of RORγt.

Authors:  Xiunan Wang; Yan Yang; Dandan Ren; Yuanyuan Xia; Wenguang He; Qingsi Wu; Junling Zhang; Miao Liu; Yinan Du; Cuiping Ren; Bin Li; Jijia Shen; Yuxia Zhang
Journal:  Br J Pharmacol       Date:  2020-03-23       Impact factor: 8.739

Review 6.  Common and Novel Markers for Measuring Inflammation and Oxidative Stress Ex Vivo in Research and Clinical Practice-Which to Use Regarding Disease Outcomes?

Authors:  Alain Menzel; Hanen Samouda; Francois Dohet; Suva Loap; Mohammed S Ellulu; Torsten Bohn
Journal:  Antioxidants (Basel)       Date:  2021-03-09

7.  The neutrophil antimicrobial peptide cathelicidin promotes Th17 differentiation.

Authors:  Danielle Minns; Katie J Smith; Virginia Alessandrini; Gareth Hardisty; Lauren Melrose; Lucy Jackson-Jones; Andrew S MacDonald; Donald J Davidson; Emily Gwyer Findlay
Journal:  Nat Commun       Date:  2021-02-24       Impact factor: 14.919

Review 8.  Moving towards personalized treatments of immune-related adverse events.

Authors:  Khashayar Esfahani; Arielle Elkrief; Cassandra Calabrese; Réjean Lapointe; Marie Hudson; Bertrand Routy; Wilson H Miller; Leonard Calabrese
Journal:  Nat Rev Clin Oncol       Date:  2020-04-03       Impact factor: 66.675

Review 9.  Mechanisms Driving Immune-Related Adverse Events in Cancer Patients Treated with Immune Checkpoint Inhibitors.

Authors:  David J Lee; Howard J Lee; Jocelyn R Farmer; Kerry L Reynolds
Journal:  Curr Cardiol Rep       Date:  2021-07-01       Impact factor: 2.931

Review 10.  Sexual dimorphism in immunometabolism and autoimmunity: Impact on personalized medicine.

Authors:  Robbie S J Manuel; Yun Liang
Journal:  Autoimmun Rev       Date:  2021-02-17       Impact factor: 9.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.